Ironwood CEO Tom McCourt
More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward
Ironwood Pharmaceuticals has walked a less-than-easy path the past few years with a proxy-driven shakeup and multiple clinical failures rocking the company. Now under new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.